Top 3 Skyrizi Manufacturers (2026 Audit Report)

H2 2026 Market Trends Analysis for Skyrizi (risankizumab)

As of the second half of 2026, Skyrizi (risankizumab), developed by AbbVie, continues to solidify its position as a leading biologic therapy in the immunology market, particularly within the interleukin-23 (IL-23) inhibitor class. The H2 2026 landscape reflects expanded indications, intensified competition, evolving payer dynamics, and growing real-world evidence supporting long-term efficacy and safety.

1. Expanded Indication Uptake

By H2 2026, Skyrizi has gained broader global adoption across its approved indications:
– Psoriasis: Remains the cornerstone of Skyrizi’s success, with high market penetration in moderate-to-severe plaque psoriasis. Recent real-world studies confirm >90% of patients achieve PASI 90 at one year, reinforcing its status as a first-line biologic.
– Psoriatic Arthritis (PsA): Increased prescribing in PsA, supported by long-term data from the KEEPsAKE trials showing sustained inhibition of structural damage and improved physical function.
– Crohn’s Disease: Uptake is accelerating following positive Phase 3 ADVANCE and MOTIVATE trial results. Skyrizi is increasingly positioned after failure of TNF inhibitors, with gastroenterologists citing its favorable safety profile compared to JAK inhibitors.
– Ulcerative Colitis (UC): Regulatory approvals in key markets (including Japan and EU expansion) in late 2025 have driven early adoption in H2 2026, competing directly with other IL-23 and integrin inhibitors.

2. Competitive Landscape Intensifies

Skyrizi faces growing competition:
– IL-23 Inhibitors: Tremfya (guselkumab) and Ilumya (tildrakizumab) maintain strong presence in psoriasis, though Skyrizi leads in market share due to superior efficacy data and longer dosing intervals (every 12 weeks after loading).
– IL-17 Inhibitors: Cosentyx (secukinumab) and Taltz (ixekizumab) remain popular, especially in patients with concomitant axial involvement, but Skyrizi is gaining ground due to lower infection risk.
– Biosimilars Impact: TNF inhibitors like Humira face widespread biosimilar competition, which indirectly benefits Skyrizi as payers and physicians shift toward newer, more targeted agents with better safety and convenience.

3. Payer and Reimbursement Dynamics

In the U.S., Skyrizi maintains favorable formulary positioning due to AbbVie’s risk-sharing agreements and patient support programs. However, increasing scrutiny from PBMs on high biologic costs has led to more restrictive prior authorization requirements. In Europe, NICE and other HTA bodies have broadly endorsed Skyrizi for psoriasis and Crohn’s, though budget impact analyses are prompting managed access agreements in countries like Germany and France.

4. Launch of Subcutaneous and Dosing Convenience

Skyrizi’s subcutaneous, self-administered formulation continues to be a key differentiator. The extended dosing interval (quarterly after initial doses) improves adherence and reduces healthcare resource utilization, appealing to both patients and providers.

5. Pipeline and Future Outlook

Late-phase trials for Skyrizi in axial spondyloarthritis (axSpA) are underway, with interim data expected in Q4 2026. Positive results could open a significant new market. Additionally, AbbVie is exploring combination therapies and biomarker-driven treatment approaches to further personalize care.

6. Sales Performance

Global sales for Skyrizi are projected to exceed $6.5 billion in 2026, with H2 growth driven by Crohn’s and UC adoption. It ranks among the top 10 highest-selling pharmaceuticals worldwide, reflecting its expanding therapeutic footprint.

---

Conclusion:
In H2 2026, Skyrizi remains a dominant force in the immunology market, leveraging strong clinical data, convenient dosing, and lifecycle management to maintain growth amid rising competition. Its success in entering inflammatory bowel disease (IBD) markets marks a strategic inflection point, positioning Skyrizi as a multi-indication powerhouse with sustained commercial momentum through the late 2020s.

Common Pitfalls Sourcing Skyrizi (Quality, IP)

Sourcing Skyrizi (risankizumab), a biologic medication used to treat autoimmune conditions like psoriasis and Crohn’s disease, involves significant risks related to product quality and intellectual property (IP) rights. Organizations and individuals must be vigilant to avoid these common pitfalls:

Substandard or Counterfeit Products

One of the most critical risks in sourcing Skyrizi is encountering substandard or counterfeit versions, particularly through unregulated or unauthorized suppliers. These products may lack proper active ingredients, contain incorrect dosages, or be contaminated, posing serious health risks to patients. Counterfeits are often indistinguishable from genuine products in packaging, making visual inspection unreliable.

Lack of Cold Chain Integrity

Skyrizi is a biologic that requires strict temperature control during storage and transportation (typically 2°C to 8°C). Sourcing through non-compliant channels increases the risk of temperature excursions, which can degrade the drug and reduce its efficacy. Poor cold chain management is a frequent issue with gray market suppliers or unauthorized distributors.

Intellectual Property Infringement

Skyrizi is protected by patents and regulatory exclusivities held by AbbVie (marketing the drug globally) and its collaborator, Boehringer Ingelheim. Sourcing biosimilars or unauthorized versions before patent expiration may constitute IP infringement. Even after biosimilar entry, only approved versions from licensed manufacturers should be considered to avoid legal exposure.

Unauthorized Distribution Channels

Purchasing Skyrizi from unauthorized distributors, online pharmacies, or third-party resellers increases the likelihood of receiving falsified products. These channels often bypass regulatory oversight, making traceability and authenticity verification difficult. Legitimate sourcing should occur through approved wholesalers or directly from authorized suppliers.

Inadequate Regulatory Compliance

Different countries have varying regulations regarding the import and distribution of biologics. Sourcing Skyrizi across borders without adhering to local regulatory requirements—such as import licenses, customs clearance, or pharmacovigilance reporting—can lead to legal penalties and supply chain disruptions.

Lack of Traceability and Documentation

Proper sourcing requires full documentation, including batch numbers, certificates of analysis, and chain-of-custody records. Failure to maintain or verify these documents increases the risk of unknowingly distributing compromised or illegal products and complicates recall efforts in case of safety issues.

Overlooking Biosimilar Authorization Status

As biosimilars of Skyrizi may enter the market after patent expiry, it’s essential to verify that any biosimilar product is approved by relevant regulatory authorities (e.g., FDA, EMA). Sourcing unapproved biosimilars—even if chemically similar—can result in quality failures and regulatory non-compliance.

Avoiding these pitfalls requires sourcing through reputable, authorized channels, conducting due diligence on suppliers, and maintaining strict adherence to regulatory and quality standards.

Logistics & Compliance Guide for SKYRIZI® (risankizumab-rzaa)

This guide outlines the essential logistics and compliance requirements for the storage, handling, distribution, and administration of SKYRIZI®, an interleukin-23 antagonist indicated for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Adherence to these guidelines ensures product integrity, patient safety, and regulatory compliance.

Storage Conditions

• Refrigerated Storage: Store SKYRIZI® prefilled syringes and autoinjectors in the original carton at 2°C to 8°C (36°F to 46°F) to protect from light.
• Avoid Freezing: Do not freeze SKYRIZI®. Discard if the product has been frozen.
• Room Temperature Storage: SKYRIZI® may be stored at room temperature up to 30°C (86°F) for a single period of up to 14 days. Once removed from refrigeration, it must be used within 14 days or discarded, whichever comes first. Do not return to the refrigerator after being stored at room temperature.
• Original Packaging: Always retain the product in its original carton to protect from light until ready for use.

Transportation Requirements

• Cold Chain Management: During shipping, SKYRIZI® must be maintained within the 2°C to 8°C range using validated cold chain packaging (e.g., refrigerated trucks, insulated shippers with cold packs).
• Temperature Monitoring: Use temperature monitoring devices (e.g., data loggers) to verify conditions throughout transit. Documentation must be retained per regulatory requirements.
• Chain of Custody: Ensure accountability at each transfer point. Shipments should be received and logged promptly upon arrival with temperature verification.
• Expedited Handling: Minimize time outside refrigerated conditions during shipping and handling. Use overnight or time-critical shipping as appropriate.

Handling and Preparation

• Visual Inspection: Prior to administration, inspect the solution for particulate matter and discoloration. SKYRIZI® should be a clear to slightly opalescent, colorless to pale yellow solution. Do not use if cloudy, discolored, or contains particles.
• Aseptic Technique: Prepare and administer SKYRIZI® using aseptic techniques. The prefilled syringe or autoinjector is for single use only.
• Needle Safety: Use caution to avoid needlestick injuries. Dispose of used syringes or autoinjectors in an FDA-cleared sharps disposal container.

Patient Distribution and Dispensing

• Authorized Channels: SKYRIZI® is distributed through specialty pharmacies and authorized healthcare providers only. It is not available in retail pharmacies.
• Patient Verification: Confirm patient eligibility, prescription validity, and prior authorization (if required) before dispensing.
• Patient Education: Provide patients with the FDA-approved Medication Guide. Educate on proper storage (including room temperature allowance), self-injection technique (if applicable), and reporting adverse events.
• Documentation: Maintain accurate records of dispensing, including patient name, dose, lot number, expiration date, and date dispensed.

Regulatory Compliance

• FDA Labeling: Comply with all FDA-approved labeling, including Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, and Adverse Reactions.
• REMS Program: SKYRIZI® is not currently subject to a Risk Evaluation and Mitigation Strategy (REMS) program. Confirm current status via the FDA website or manufacturer updates.
• Pharmacovigilance: Report all adverse events and medication errors to the manufacturer (AbbVie) and FDA MedWatch program per regulatory timelines.
• Record Retention: Maintain distribution, storage, and handling records for a minimum of 5 years, or as required by local regulations.

Environmental and Disposal Compliance

• Sharps Disposal: Used SKYRIZI® devices must be discarded in a puncture-resistant, leak-proof sharps container that complies with OSHA and local regulations.
• Drug Waste: Unused or expired SKYRIZI® should be disposed of in accordance with federal, state, and local regulations for pharmaceutical waste. Do not flush or pour down the drain.
• Cold Pack Disposal: Gel packs used in shipping should be disposed of according to manufacturer instructions and environmental guidelines.

Training and Accountability

• Staff Training: Ensure all personnel involved in handling, storing, or administering SKYRIZI® are trained on proper procedures, safety protocols, and compliance requirements.
• Audit Preparedness: Maintain systems for internal audits and be prepared for regulatory inspections. Documentation must be accurate, complete, and readily accessible.

For the most current information, refer to the official SKYRIZI® Prescribing Information and consult with AbbVie Medical Affairs or Specialty Pharmacy Support.

Declaration: Companies listed are verified based on web presence, factory images, and manufacturing DNA matching. Scores are algorithmically calculated.